GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » Other Income (Expense)

NervGen Pharma (TSXV:NGEN) Other Income (Expense) : C$-0.43 Mil (TTM As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma Other Income (Expense)?

NervGen Pharma's other income expense for the NervGen Pharma's pretax income for the three months ended in Mar. 2025 was C$1.98 Mil. Its other income expense for the trailing twelve months (TTM) ended in Mar. 2025 was C$-0.43 Mil.

NervGen Pharma Other Income (Expense) Historical Data

The historical data trend for NervGen Pharma's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Other Income (Expense) Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Income (Expense)
Get a 7-Day Free Trial -0.01 0.05 2.62 -5.16 0.11

NervGen Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.52 -2.12 1.69 -1.97 1.98

NervGen Pharma Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NervGen Pharma  (TSXV:NGEN) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

NervGen Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » Other Income (Expense)
Comparable Companies
NEOE:CYBN TSX:FRX TSX:EPRX XCNQ:METX TSX:TH TSXV:ARCH TSX:MSCL XCNQ:DRUG TSX:MDNA XCNQ:GLAB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
NGENF:USA 9UA:Germany
Address
112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
Website
https://www.nervgen.com
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.
Executives
John Ruffolo Director
Krista Mckerracher Director
William Joseph Radvak Director
Harold Punnett 10% Security Holder, Director
Robert Pilz Senior Officer

NervGen Pharma Headlines

No Headlines